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Introduction: A collision tumor is the meeting and eventual intermingling of two malignant neoplasms arising
from independent topographical sites. Collision metastasis of carcinomas in the lymph nodes is a rare event. A
literature search revealed only three cases of such a collision metastasis of prostatic and urothelial carcinoma, and
only one of those cases had used immunohistochemical stains to distinguish the two tumors.
Case presentation: We encountered a case of this rare entity in an 83-year-old African-American man who
presented to our facility with increasing pelvic pain after a transurethral resection of a high-grade bladder tumor
and a negative metastatic computed tomography chest, abdomen and pelvic scan investigation. A radical
cystoprostatectomy was subsequently performed revealing a multi-centric, high-grade, ill-defined infiltrating
urothelial carcinoma infiltrating the right pericystic soft tissue. A histopathological examination of the prostate
revealed a multi-centric adenocarcinoma (Gleason 4 + 4) involving two pelvic lymph nodes. Interestingly, while the
right pelvic lymph node was positive for metastatic prostatic adenocarcinoma alone, immunohistochemical studies
of the left pelvic lymph node revealed a dual metastatic urothelial (cytokeratin-7 and pan-cytokeratin positive,
prostate-specific antigen and cytokeratin-20 negative) and prostatic (prostate-specific antigen and pan-cytokeratin
positive, cytokeratin-7 and cytokeratin-20 negative) carcinoma.
Conclusions: The collision of metastatic urothelial carcinoma and prostatic adenocarcinoma is unusual, and their
biological behavior remains uncertain. A high index of suspicion along with thorough clinical examination and
immunohistochemical stain results are an integral part of differentiating collision of urothelial carcinoma from
prostate carcinoma, particularly when the two tumors are in close proximity with overlapping histological features.
Keywords: Carcinoma, collision tumor, prostate, urothelialIntroduction
Collision tumors demonstrating the mixing and mingling
of two carcinomas from two distinct topographic origins
at a metastatic site are rare entities [1]. These tumors are
difficult to diagnose preoperatively, and pathological iden-
tification of the dual components is often the only way to
make a correct diagnosis [2]. We report a rare case of col-
lision tumor between urothelial and prostate metastatic
cancers to the same pelvic lymph node. An 83-year-old
African-American man underwent a radical cystoprosta-
tectomy after a transurethral resection (TUR) revealed a* Correspondence: Tapan.Bhavsar@tuhs.temple.edu
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reproduction in any medium, provided the orhigh-grade bladder tumor. A histopathological examin-
ation of the bladder tumor confirmed a high-grade papil-
lary urothelial carcinoma and histopathological evaluation
of the prostate revealed a bilateral, multi-centric adenocar-
cinoma (Gleason score 4 + 4). The left pelvic lymph node
revealed a focus of dual metastatic urothelial and prostatic
carcinomas, confirmed by a panel of immunohistochem-
ical stains including cytokeratin (CK)7, CK20, pan-
cytokeratin (pan-CK) and prostate-specific antigen (PSA).
Collision metastases of carcinomas from two separate pri-
mary lesions to the same lymph node are rare. A literature
search revealed only three cases of such a synchronous
metastatic collision tumor involving metastatic prostatic
and urothelial carcinomas; only one of those cases used
immunohistochemical stains to distinguish the two tumors.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 High-grade urothelial carcinoma, original tumor
(hematoxylin and eosin stain, original magnification× 100).
Figure 2 Prostate adenocarcinoma, original tumor
(hematoxylin and eosin stain, original magnification× 400).
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using immunohistochemical staining to definitively distin-
guish the metastatic urothelial cancer from the prostatic
focus [1,3,4].
Case presentation
Our patient was an 83-year-old African-American man,
who was referred to our institution after originally pre-
senting with difficult Foley placement at a local hospital.
His medical history was relevant for benign prostatic
hyperplasia, chronic renal insufficiency, arthritis and
hypertension. His social history included tobacco use in
the remote past. His vital signs and results of a review of
systems were unremarkable. Results of a blood investiga-
tion showed a significant left shift with 82% segmented
neutrophils. Urine analysis revealed cloudy urine, posi-
tive for leukocyte esterase, nitrites, small amount of
blood and ketones. Microscopic examination of his urine
showed 10 to 20 red blood cells (RBC) per high power
field (HPF) and a field full of white blood cells (WBC)
and bacteria. Our patient underwent cytoscopy after
blood oozed out during initial catheter insertion. A
complete investigation for hematuria including a com-
puted tomography (CT) scan was performed that
revealed a bladder mass. A TUR was undertaken, and
histopathology confirmed the mass as being a high-
grade bladder carcinoma. A follow-up metastatic investi-
gation including a CT scan of the chest, abdomen, pelvis
and bone were negative. Our patient developed increas-
ing pelvic pain and significant hematuria. A radical
cystoprostatectomy was subsequently performed reveal-
ing a multi-centric, ill-defined urothelial carcinoma
(9 × 7 cm) infiltrating the right pericystic soft tissue and
encompassing the right ureteral orifice. Our patient tol-
erated the surgical procedure well. His post-operative
course was complicated by right deep venous thrombosis
occluding the right common femoral vein. A histopatho-
logical examination of the bladder tumor revealed a high-
grade papillary urothelial carcinoma (Figure 1) completely
involving the dome and posterior wall, and partially in-
volving the anterior and right lateral walls. The tumor
extended into the perivascular soft tissue and metastatic
urothelial carcinoma was identified in a left pelvic lymph
node (staging: pT3; pN2; pMx). Additionally, histopatho-
logical examination of the prostate revealed a bilateral,
multi-centric adenocarcinoma, Gleason 4+ 4 (Figure 2)
with perineural and lymphatic/vascular invasion. Meta-
static prostatic adenocarcinoma was also identified involv-
ing the left and right pelvic lymph nodes (staging: pT3a;
pN1; pMx). Interestingly, the left pelvic lymph node
revealed a focus of both metastatic urothelial and prostatic
carcinomas (Figures 3, 4). The presence of two tumor
types colliding in the same lymph node was confirmed
using immunohistochemical stains, including CK7 andCK20, pan-CK and PSA. Additionally, both the primary
tumors were stained with the same panel as an internal
control. The focus of metastatic urothelial carcinoma was
positive for CK7 (Figure 5), pan-CK, and negative for
CK20, while prostatic carcinoma was negative for CK7
(Figure 6), CK20, and positive for pan-CK. In addition, the
metastatic urothelial carcinoma stained negative for PSA
(Figure 7), while the prostatic carcinoma was positive
(Figure 8).Discussion
Collision tumors have been defined differently by various
authors with minor variations. Meyer [5] defined this entity
as ‘the meeting and eventual intermingling of two malig-
nant neoplasms arising at independent topographical sites’.
Dodge [6] suggested that, in order to accept a tumor of
mixed structure as a collision tumor (that is, as the growing
together of two independently arising neoplasms), there
Figure 3 Metastatic urothelial carcinoma in the lymph node
(hematoxylin and eosin stain, original magnification× 100).
Figure 5 Metastatic urothelial carcinoma in the lymph node
(cytokeratin stain, original magnification ×100).
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histological patterns; furthermore, if both types of tumor
metastasized, then the two types of growth should be
clearly separated in the metastases also. Dodge’s definition
further requires an absence of any area showing a transi-
tional pattern that suggests a structure intermediate be-
tween the two tumor types. From Spagnolo and Heenan’s
[7] point of view, collision tumors should be recognized on
the basis of: (i) Two distinct, topographically separate sites
of origin for the two components, and (ii) at least some
separation between the two components, despite intimate
mixing at the point of juxtaposition. However, in contrast
to Dodge’s definition, these authors [7] allow some transi-
tional patterns to be seen in the area of collision, and the
same criteria would be applicable to metastases. This is in
distinction to combination or composite tumors,
which reveal divergent histologic findings and can,Figure 4 Metastatic prostatic adenocarcinoma in the lymph
node (hematoxylin and eosin stain, original
magnification× 100).reveal different cellular lineages but arise from a com-
mon source [2].
Collision lymph node metastases of two carcinomas
from separate sites are very rare. To the best of our
knowledge, only four cases have been reported in the lit-
erature; three of which were collision metastases of
prostate and bladder carcinoma [1,3,4], and one breast
carcinoma metastasizing to a lymph node along with a
malignant lymphoma [8].
Collision tumors, in addition to a metastatic phenomenon,
such as breast carcinoma metastasizing to meningioma [9],
can occur within the same organ, such as renal cell carcin-
oma with transitional cell carcinoma [10] or in adjacent
organs, such as sigmoid adenocarcinoma with urinary blad-
der transitional carcinoma [11]. The incidence of this
phenomenon from carcinoma arising from the genitourinary
organs in comparison to other organs is relatively high dueFigure 6 Metastatic prostatic adenocarcinoma in the lymph
node (cytokeratin stain, original magnification× 100).
Figure 7 Metastatic urothelial carcinoma in the lymph node
(prostate-specific antigen stain, original magnification × 100).
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other organs.
Several hypotheses have been suggested as mechanisms
for collision tumors. The simplest is that the two primary
tumors occurred in continuity by a chance accidental
‘meeting’. Two different tumors may develop contiguously
because the region is altered by the same carcinogenic
stimuli. Another hypothesis is that the presence of the first
tumor alters the microenvironment, making the develop-
ment of the second adjacent tumor more likely.
The collision of metastatic urothelial carcinoma and
prostatic adenocarcinoma is unusual. The distinguishing
histologic characteristics may not be clearly apparent; in
fact, the two tumors may not be clearly separated in the
metastases at all. This is more evident when both
the tumors are poorly differentiated, equally demonstrat-
ing hyperchromasia, prominent nucleoli, atypia, and
pleomorphism.Figure 8 Metastatic prostatic adenocarcinoma in the lymph
node (prostate-specific antigen stain, original
magnification× 100).The use of immunohistochemical stains can be an inte-
gral part of differentiating high-grade urothelial carcinoma
from prostate carcinoma, particularly when the two
tumors are in close proximity with overlapping histologic
features.
The judicious use of immunostains consisting of CK7,
CK20 and PSA in differentiating prostate adenocarcin-
oma and bladder urothelial carcinoma has been investi-
gated and advocated. Two studies demonstrate the
usefulness of concomitant CK7 and CK20 staining to dis-
tinguish urothelial from prostate carcinoma, and merits
attention. In one study, Wang et al. [12] stained 19 cases
of urothelial carcinoma and 13 cases of prostatic carcin-
omas with CK7 and CK20, among multiple other tumor
types. The results indicated that for urothelial carcinoma,
overall 100% were CK7+, 89% were CK7+/CK20+, and
none were CK7-/CK20-; however, for prostate carcin-
omas, 62% were CK7-/CK20-, and only 8% was CK7+ [4].
On a similar note, Chu et al. [13] in their study staining
for multiple epithelial neoplasms, demonstrated 88%
of the urothelial carcinomas to be CK7+, 25% to be
CK7+/CK20+, while 100% of the prostate carcinomas to
be CK7-/CK20-. Another study by Bassily et al. [14] eval-
uated only prostate and urothelial carcinomas, staining
both with CK7, CK20, and PSA. The results showed that
23 (82%) of 28 urothelial carcinomas were CK7+, 18
(64%) were CK20+ and only 6 (10%) of 59 prostate car-
cinomas were both CK7+ and CK20+. Even though 48
(81%) of 59 prostate carcinomas were negative for both
cytokeratins, most of their urothelial tumors stained for
CK7, CK20, or both. Conversely, 58 (98%) of 59 prostate
carcinomas stained for PSA, but no urothelial tumors
stained for PSA. The findings suggested that a combin-
ation of PSA, CK7, and CK20 is more helpful than CK7
and CK20 alone [14]. In accordance with these findings,
although we suspected both urothelial carcinoma and
prostate adenocarcinoma morphologically in the same
lymph node, we used immunohistochemical stains to
confirm and differentiate the exact metastatic foci of each
tumor. The focus of metastatic urothelial carcinoma
was positive for CK7 and pan-CK, and negative for
PSA and CK20, while the prostatic carcinoma was
positive for PSA and pan-CK and negative for CK7
and CK20.
The morphologic differentiation of metastatic urothe-
lial from prostate carcinoma in the collision tumor is as
important as the differentiation between the correspond-
ing primary tumors, especially poorly differentiated pros-
tate adenocarcinoma extending into the bladder neck
versus high-grade urothelial carcinoma extending into
the bladder neck and prostate. Since both these tumors
can present with similar high-grade histologic and nu-
clear features, distinction by morphology alone can be
difficult. In a study in 1996, Lindeman and Weidner [15]
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tumors and 5 poorly differentiated carcinomas of uncer-
tain type (prostatic or urothelial origin) located at the
junction of bladder neck and prostate with CK7, CK20,
PSA, PAP (Prostatic Acid Phosphatase) and CEA (Carci-
noembryonic Antigen). Of the 5 tumors, 3 stained for
three markers including PSA, PAP and CK7. This im-
munologic overlap of the urothelial and prostatic tissue
has been thought to be due to a common derivation from
the urogenital sinus. Of course, the tailor-fit distinction
into either category in these complex cases is not
feasible.
Although usually considered to be merely an academic
curiosity, collision tumors are clinically relevant in that
the individual tumors may require different treatments.
The biological behavior remains uncertain; however,
most of the collision tumors are thought to carry a poor
prognosis. This poor prognosis of collision tumor is
dependent on the biological behavior of each original
tumor or on the progress of the disease, irrespective of
the collision in different nodes. In one such case, the
presence and degree of differentiation of an adenocar-
cinoma component seemed to be more detrimental than
a carcinoid component [16]. Determination of somatic
genetic alterations [17] may complement the morpho-
logical and immunological criteria to determine the
biclonal origin of a collision tumor.
Conclusions
The significance of collision tumors is threefold; the
diagnosis of one type of cancer does not rule out the
simultaneous presence or later development of a differ-
ent type of cancer, a high index of suspicion is warranted
while evaluating lymph nodes in a patient diagnosed
with two distinct types of cancer, and the use of immu-
nohistochemical stains can be an integral part of differ-
entiating all types of collision tumors from both the
genitourinary tract and other organ systems.
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